7 recruiting. 7 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 7 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Neoadjuvant Chemoimmunotherapy: new trials by email Literature Review of Neoadjuvant Chemoimmunotherapy trials Research Report on Neoadjuvant Chemoimmunotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05) Iparomlimab and Tuvonralimab, Oxaliplatin, Tegafur - Immunotherapy, Gastric Cancer (GC) | Phase 2 | Recruiting | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 40 | 2025-07-23 | 2025-09-10 |
| NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study Neoadjuvant chemo-immunotherapy, Extended pleurectomy/decortication in case of reaching operability - Pleural Epithelioid Mesothelioma, Mesothelioma; Pleura | Phase 1 / Phase 2 | Recruiting | University Hospital, Antwerp | 37 | 2025-07-22 | 2025-08-13 |
| Neoadjuvant Immunochemotherapy in PD-L1-negative LACC Camrelizumab, Paclitaxel-albumin, Cisplatin - Cervical Cancer, Locally Advanced Cervical Cancer | Phase 2 | Recruiting | Tongji Hospital | 40 | 2024-09-12 | 2025-03-20 |
| Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer Cadonilimab, Paclitaxel-albumin, Cisplatin - Cervical Cancer, Neoadjuvant Chemoimmunotherapy | Phase 2 | Recruiting | Tongji Hospital | 50 | 2024-09-03 | 2024-09-19 |
| Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer Camrelizumab, Cisplatin, Nab paclitaxel - Cervical Cancer, Neoadjuvant Chemoimmunotherapy | Phase 2 | Recruiting | Tongji Hospital | 40 | 2024-05-08 | 2024-11-05 |
| Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC Camrelizumab, Cisplatin, Nab paclitaxel - Cervical Cancer, Locally Advanced Cervical Cancer | Phase 2 / Phase 3 | Recruiting | Tongji Hospital | 440 | 2024-04-22 | 2024-10-30 |
| Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma Tislelizumab - Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy | Phase 2 | Recruiting | Guo Xufeng | 73 | 2023-09-07 | 2023-09-28 |
Uterine Cervical Neoplasms (4) · Esophageal Squamous Cell Carcinoma (1) · Mesothelioma, Malignant (1) · Stomach Neoplasms (1)
Neoplasms (7) · Neoplasms by Site (7) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Genital Diseases (4) · Genital Diseases, Female (4) · Genital Neoplasms, Female (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Uterine Cervical Diseases (4) · Uterine Diseases (4) · Uterine Neoplasms (4) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2)
Cisplatin (4) · camrelizumab (3) · Taxes (2) · Albumin-Bound Paclitaxel (1) · Biopsy (1) · Brachytherapy (1) · Carboplatin (1) · Cerebral Decortication (1) · Conization (1) · Oxaliplatin (1) · Radiotherapy (1) · Tegafur (1) · tislelizumab (1)
Tongji Hospital (4) · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (1) · Guo Xufeng (1) · University Hospital, Antwerp (1)
China (6) · Belgium (1)
Ding Ma (4) · Bin Wang (1) · Changqing Pan (1)
PMID 24419108, PMID 34160577, PMID 41582028, PMID 42172490
2023 (1)